Chemical lipid measurement is routinely performed for cardiovascular risk assessment. Conventional lipid assays determine the amount of cholesterol or triglyceride carried by all particles within a lipoprotein class. Cholesterol measurements included in this pilot study were total cholesterol (TC), Low Density Lipoprotein cholesterol (LDL-C), High Density Lipoprotein cholesterol (HDL-C), Very Low Density Lipoprotein cholesterol (VLDL) and triglyceride. This study was an observational retrospective investigation of cardiology patients at a Central Texas cardiology clinic housed within a major hospital. Thirty-nine cardiology patients were recruited who were 18 years of age and older. The sample was gathered and evaluated through analysis of the hospital’s computerized billing system and patient’s medical charts. A list of patients who had been given a heart catheterization to establish heart disease was acquired. Following this, patient’s names were entered into the hospital billing database to establish who had received a nuclear magnetic resonance screening. The effects of statin (Zocor, Lipitor, Pravachol, Lescol, Advicor) and fibrate (Tricor) therapy on cholesterol and triglyceride levels were investigated in an effort to determine trends for an expanded research project. Repeated measure ANOVA was calculated to determine differences in TC, LDL-C, HDL-C, VLDL and triglyceride after four weeks of therapy. Though no significant differences were found, possibly due to the small sample size and study duration, interesting trends developed. Mean TC from T1 to T2 decreased by 14.21 mg/dL, LDL-C decreased by 9.11 mg/dL, triglyceride decreased by 20.08 mg/dL, and HDL-C increased by 2.33 mg/dL. Statins are a class of widely used drugs that reduce cholesterol production in the liver through HMG-CoA reductase inhibition, with additional effectiveness in preventing stroke. Patients who have established coronary heart disease or those who are at high risk of heart disease, who have not been able to modify cholesterol levels through diet and exercise, can benefit from this approach to lipid management. Not only does it lower cholesterol but statin therapy may also benefit patients with persistent inflammation as measured by high levels of C-reactive protein (CRP), a marker for predicting heart disease risk even in patients with normal cholesterol levels. A growing number of trials that used fibrates with other lipid-altering agents have shown that these drugs are effective for reducing total cholesterol, LDL-C and triglycerides, and for increasing HDL-C levels. Future research will include the influences of statin and fibrate therapy on arterial inflammatory markers.